Oslo, Norway, August 31, 2021: It is based on the stock exchange announcement from Photocure ASA (“Photocure” or the “society“) published on August 30, 2021 for the exercise of stock options.
The price of option shares sold by lead insider Geoffrey Coy, VP & General Manager US Operations, was set at NOK 113.6148 per share.
The main insider who exercised options used the net proceeds from the sale of option shares to buy 7,126 shares of Photocure at a price per share of NOK 113,6148 as follows:
The shares will be acquired from Photocure’s own shares at the specified price. After the transaction, Photocure will hold 21,010 treasury shares.
The primary insider report in accordance with Article 19 of the Market Abuse Regulation is attached.
For more information please contact:
Chief Financial Officer Erik Dahl
Tel: +47 450 55 000
Email: [email protected]
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology that makes cancer cells glow bright pink has led to better health outcomes for patients around the world. Photocure is headquartered in Oslo, Norway and is listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com
All trademarks mentioned in this press release are legally protected and registered trademarks of Photocure ASA.
This information is subject to disclosure requirements under the Market Abuse Regulation Articles 19 and 5-12 of the Norwegian Securities Trading Act.
(c) until 2021. All rights reserved., Source Press Releases – English